Beikang Medical and Haier Biomedical Forge Strategic Alliance to Develop Cryopreservation Solutions for Assisted Reproduction
On July 13, in Qingdao, Shandong Province, China, Suzhou Beikang Medical Co., Ltd. (hereinafter referred to as “Beikang Medical”) and Qingdao Haier Biomedical Co., Ltd. (hereinafter referred to as “Haier Biomedical”) officially signed a strategic cooperation agreement. The two parties will engage in collaborative research and development in the field of cryopreservation for assisted reproduction, jointly providing cryogenic storage solutions for the assisted reproductive technology industry. This marks another deep industrial collaboration following Beikang Medical’s partnership with the Haichuang Fund of Funds. Dr. Liu Zhanjie, Founder of Haier Biomedical; Mr. Liu Dong, General Manager of the Haichuang Qianfeng Fund of Funds; Dr. Liang Bo, Founder of Beikang Medical; and other distinguished guests attended the signing ceremony.
Strategic Cooperation Signing Ceremony
Embryology laboratories, andrology laboratories, and cryogenic storage laboratories are critical components of the field of assisted reproductive technology (ART). Among these, cryopreservation technology, as an indispensable technique in ART procedures, has been widely applied to safeguard and offer hope for fulfilling the fertility needs and reproductive health of individuals requiring assistance. The 2018 "Chinese Expert Consensus on the Storage Duration of Frozen Embryos" states that frozen embryos should ideally be used within five years, and the maximum storage and clinical usage period for couples planning future childbirth should not exceed ten years. This implies that ART centers currently need to make substantial and annually increasing long-term investments in storage resources, including storage containers, storage space, and management and maintenance operations. With the rising number of infertile couples and advanced maternal age pregnancies, the gap in demand for fertility preservation continues to widen, indicating significant market potential.
Haier Biomedical is the first enterprise in Qingdao to be listed on the STAR Market. Starting with the R&D, production, and sales of biomedical cold storage equipment, the company has comprehensively promoted the integrated innovation of IoT technology and cold storage technology. By combining IoT software and hardware based on network communication and radio-frequency identification (RFID) technologies with its self-developed cold storage products, Haier Biomedical has upgraded traditional storage equipment into IoT-enabled scenario solutions. This approach meets the evolving needs of users in clinical blood use, vaccine inoculation, biobank applications, and other areas, thereby building an IoT technology ecosystem. Haier Biomedical took the lead in breaking foreign monopolies by independently developing and mastering core ultra-low temperature refrigeration technologies, becoming the world’s only provider of biomedical cold storage equipment covering the full temperature range from -196°C to 8°C.
Haier Biomedical Product Overview
As the first IVD company in China’s assisted reproductive technology sector to be listed on the Hong Kong Stock Exchange, Beikang Medical has always adhered to the philosophy of “developing innovative products” and persisted in pursuing compliant pathways for R&D, registration, and certification. As early as 2015, Beikang Medical initiated the research and development of intelligent embryo storage equipment and management systems. Its independently developed, domestically produced intelligent liquid nitrogen tank (BCT38) and ultra-low temperature storage unit (BSG800A) help ensure the safety of fertility preservation and the scientific rigor of laboratory management. These products are expected to obtain registration certificates in 2022 and 2023, respectively, with the BCT38 poised to become the first intelligent liquid nitrogen tank in China to receive a Class II medical device registration certificate.
Beikang Medical Intelligent Cryogenic Storage System
Through this strategic partnership, both parties will leverage their respective advantages in products, channels, and other resources to jointly build cryopreservation solutions for the field of assisted reproduction. Collaboration will span market promotion, technical support, joint R&D, and regulatory registration and certification, thereby driving the comprehensive expansion of fertility preservation application scenarios. By empowering the development of the assisted reproduction industry through a new model of resource sharing, the partnership aims to facilitate the rapid and effective translation of high-quality products and technologies into clinical practice, ultimately benefiting more patients.